Results of Celon Pharma S.A. research at the European Hematology Congress

The 19th Congress of the European Hematology Association, during which Celon Pharma S.A. will be presenting the latest results of research on developing innovative PI3K-delta inhibitors, will be held on 12-15 June in Milan. We wish to encourage participants to see our poster presentation entitled: “Preclinical evaluation of a novel highly potent and selective PI3K-delta inhibitor CPL-302-201 for the treatment of hematologic malignancies.”